Herantis Pharma Oyj Total Assets
Herantis Pharma Oyj total assets. Based on the latest financial reports, Herantis Pharma Oyj (HRTIS) holds total assets worth €5.11 Million EUR (≈ $5.98 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see HRTIS market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Herantis Pharma Oyj (2011–2024)
Total assets of Herantis Pharma Oyj from 2011 to 2024. This chart illustrates how Herantis Pharma Oyj's total assets have evolved over time, based on quarterly financial data. See latest Herantis Pharma Oyj stock price today for real-time trading data and today's change.
Herantis Pharma Oyj - Asset Composition Analysis
Herantis Pharma Oyj Total Assets Breakdown (December 2024)
Herantis Pharma Oyj total assets breakdown as of December 2024. Herantis Pharma Oyj's total assets of €5.11 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €634.52K | 24.7% |
| Accounts Receivable | €406.46K | 15.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Herantis Pharma Oyj's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Herantis Pharma Oyj to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Herantis Pharma Oyj's current assets represent 100.0% of total assets in 2024, an increase from 51.7% in 2011.
- Cash Position: Cash and equivalents constituted 24.7% of total assets in 2024, down from 36.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 47.0% in 2011.
- Asset Diversification: The largest asset category is cash and equivalents at 24.7% of total assets.
Herantis Pharma Oyj Competitors by Total Assets
Key competitors of Herantis Pharma Oyj based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Herantis Pharma Oyj - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.10 | 2.30 | 8.23 |
| Quick Ratio | 8.10 | 2.30 | 8.23 |
| Cash Ratio | 0.71 | 1.26 | 0.00 |
| Working Capital | €4.48 Million | €2.06 Million | €8.13 Million |
Herantis Pharma Oyj - Advanced Valuation Insights
This section examines the relationship between Herantis Pharma Oyj's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 32.88 |
| Latest Market Cap to Assets Ratio | 14.29 |
| Asset Growth Rate (YoY) | -61.9% |
| Total Assets | €2.57 Million |
| Market Capitalization | $36.75 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Herantis Pharma Oyj's assets at a significant premium (14.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Herantis Pharma Oyj's assets decreased by 61.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Herantis Pharma Oyj (2011–2024)
The table below shows the annual total assets of Herantis Pharma Oyj from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €2.57 Million ≈ $3.01 Million |
-61.89% |
| 2023-12-31 | €6.75 Million ≈ $7.89 Million |
+8.24% |
| 2022-12-31 | €6.23 Million ≈ $7.29 Million |
-9.92% |
| 2021-12-31 | €6.92 Million ≈ $8.09 Million |
-57.87% |
| 2020-12-31 | €16.42 Million ≈ $19.20 Million |
+48.32% |
| 2019-12-31 | €11.07 Million ≈ $12.94 Million |
+54.89% |
| 2018-12-31 | €7.15 Million ≈ $8.36 Million |
-38.24% |
| 2017-12-31 | €11.57 Million ≈ $13.53 Million |
+13.40% |
| 2016-12-31 | €10.21 Million ≈ $11.93 Million |
-27.56% |
| 2015-12-31 | €14.09 Million ≈ $16.47 Million |
-52.23% |
| 2014-12-31 | €29.49 Million ≈ $34.48 Million |
+1016.87% |
| 2013-12-31 | €2.64 Million ≈ $3.09 Million |
+19.42% |
| 2012-12-31 | €2.21 Million ≈ $2.59 Million |
+230.00% |
| 2011-12-31 | €670.13K ≈ $783.46K |
-- |
About Herantis Pharma Oyj
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinic… Read more